在肥胖患者中注射硫酸的最佳剂量:双盲随机试验
Silva Filho S E1, Matias G F2, Dainez S1
1Department of Anesthesiology, Hospital da Sociedade Portuguesa de Beneficência de Santos, Santos, Brazil.
Anesthesiology research and practice
|March 27, 2025
概括
根据实际体重计算硫酸剂量,与调整的理想体重相比,可以改善术后疼痛控制. 这种方法可以增强疼痛缓解,而不会显著改变水平.
科学领域:
- 麻醉学 麻醉学
- 药理学 药理学是指药理学的学科.
- 疼痛管理 疼痛管理
背景情况:
- 硫酸被认为可以减少阿片类药物消费和副作用.
- 硫酸的最佳剂量策略,特别是实际体重与调整后的理想体重,仍在争论中.
- 这项研究解决了关于硫酸剂量提高术后疼痛缓解的共识的需要.
研究的目的:
- 为了比较硫酸在术后镇痛中的疗效,当使用实际体重和调整后的理想体重计算剂量时.
- 评估不同硫酸剂量策略对疼痛评分和阿片类药物需求的影响.
- 评估度变化的临床意义及其对神经肌肉阻塞的影响.
主要方法:
- 一个前性的,随机的,双盲的,受控的临床试验,涉及75名参与者,接受目标控制的静脉静脉全身麻醉.
- 参与者被分配到三个组:对照组 (CG),基于实际体重 (AWG) 的硫酸和基于调整的理想体重 (IWG) 的硫酸.
- 术后疼痛评分,阿片类药物使用,血清度和神经肌肉阻塞延迟被测量和比较.
主要成果:
- 与对照组 (CG) 和理想体重组 (IWG) 相比,实际体重组 (AWG) 的术后疼痛得分明显较低.
- 与AWG和IWG相比,CG的阿片类药物消费量明显高于AWG和IWG,AWG和IWG之间没有显著差异.
- 硫酸的使用,无论用什么剂量方法,都能缩短神经肌肉阻塞的延迟时间,但没有达到临床显著的度增加.
结论:
- 基于实际体重的硫酸剂量优于增强术后止痛.
- 观察到的度增加没有临床意义,也没有妨碍cisatracurium的疗效.
- 实际体重剂量是优化硫酸在外科手术期间缓解疼痛的有效策略.
更多相关视频
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
10.6K
06:13Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
1.0K
相关概念视频
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.